EP2035574A1 - Utilisation de la n-acylaminoacylpeptide hydrolase (apeh) comme cible thérapeutique ou diagnostique - Google Patents

Utilisation de la n-acylaminoacylpeptide hydrolase (apeh) comme cible thérapeutique ou diagnostique

Info

Publication number
EP2035574A1
EP2035574A1 EP07725942A EP07725942A EP2035574A1 EP 2035574 A1 EP2035574 A1 EP 2035574A1 EP 07725942 A EP07725942 A EP 07725942A EP 07725942 A EP07725942 A EP 07725942A EP 2035574 A1 EP2035574 A1 EP 2035574A1
Authority
EP
European Patent Office
Prior art keywords
apeh
diseases
polypeptide
cancer
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07725942A
Other languages
German (de)
English (en)
Inventor
Stefan Golz
Ulf Brüggemeier
Andreas Geerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to EP07725942A priority Critical patent/EP2035574A1/fr
Publication of EP2035574A1 publication Critical patent/EP2035574A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une APEH humaine associée aux maladies cardio-vasculaires, au cancer, aux inflammations, aux maladies hématologiques, aux maladies neurologiques et aux maladies urologiques. L'invention concerne également des dosages permettant d'identifier des composés utilisés pour traiter ou prévenir les maladies cardio-vasculaires, le cancer, les inflammations, les maladies hématologiques, les maladies neurologiques et les maladies urologiques. L'invention concerne enfin des composés qui se lient à APEH et/ou active ou inhibe son activité ainsi que des compositions pharmaceutiques comprenant lesdits composés.
EP07725942A 2006-06-17 2007-06-11 Utilisation de la n-acylaminoacylpeptide hydrolase (apeh) comme cible thérapeutique ou diagnostique Withdrawn EP2035574A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07725942A EP2035574A1 (fr) 2006-06-17 2007-06-11 Utilisation de la n-acylaminoacylpeptide hydrolase (apeh) comme cible thérapeutique ou diagnostique

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06012459 2006-06-17
PCT/EP2007/005118 WO2007147496A1 (fr) 2006-06-17 2007-06-11 Utilisation de la n-acylaminoacylpeptide hydrolase (apeh) comme cible thérapeutique ou diagnostique
EP07725942A EP2035574A1 (fr) 2006-06-17 2007-06-11 Utilisation de la n-acylaminoacylpeptide hydrolase (apeh) comme cible thérapeutique ou diagnostique

Publications (1)

Publication Number Publication Date
EP2035574A1 true EP2035574A1 (fr) 2009-03-18

Family

ID=38544369

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07725942A Withdrawn EP2035574A1 (fr) 2006-06-17 2007-06-11 Utilisation de la n-acylaminoacylpeptide hydrolase (apeh) comme cible thérapeutique ou diagnostique

Country Status (2)

Country Link
EP (1) EP2035574A1 (fr)
WO (1) WO2007147496A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215840A1 (en) * 2002-02-01 2003-11-20 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003300815A1 (en) * 2002-12-05 2004-06-30 Incyte Corporation Protein modification and maintenance molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007147496A1 *

Also Published As

Publication number Publication date
WO2007147496A1 (fr) 2007-12-27

Similar Documents

Publication Publication Date Title
US20110033844A1 (en) Use of lysosomal carboxypeptidase c (prcp) as a therapeutic or diagnostic target
WO2007147497A2 (fr) Utilisation d'un domaine du type désintégrine et métalloprotéinase à motif de thrombospondine de type 1 (adamts1) comme cible thérapeutique et diagnostique
WO2007141004A1 (fr) Utilisation de l'adipsine (adn) comme cible thérapeutique ou diagnostique
US20070218047A1 (en) Diagnostics and Therapeutics for Diseases Associated with Kallikrein 2 (KLK2)
US20070269807A1 (en) Diagnostics and Therapeutics for Diseases Associated with Putative Cysteine Protease 1 (Prs1)
WO2007140907A1 (fr) Utilisation de sérine endopeptidase 22 (prss22) en tant que cible thérapeutique ou diagnostique
WO2007140895A1 (fr) Utilisation de la leucyl aminopeptidase 3 (lap3) en tant que cible thérapeutique ou diagnostique
EP1718759A1 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la kallicreine 3 (klk3)
US20060110783A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
WO2006013014A2 (fr) Diagnostics et therapeutiques pour maladies liees a une proteine similaire a un antigene membranaire specifique de la prostate (psmal)
US20070148175A1 (en) Diagnostics and therapeutics for diseases associated with kallikrein 12 (klk12)
WO2007140906A1 (fr) Utilisation de la leucyl/cystinyl aminopeptidase (lnpep) en tant que cible thérapeutique ou diagnostique
WO2007141005A1 (fr) Utilisation de glutamyl aminopeptidase (enpep) comme cible thérapeutique ou diagnostique
EP1633882B1 (fr) Diagnostic et therapeutique de maladies associees a une aminopeptidase specifique a leucyle insensible a la puromycine (pils)
EP1573333A1 (fr) AGENTS DE DIAGNOSTIC ET DE TRAITEMENT DE MALADIES ASSOCIEES A LA PHOSPHODIESTERASE HUMAINE 9A2 (PDE9a2)
WO2007147496A1 (fr) Utilisation de la n-acylaminoacylpeptide hydrolase (apeh) comme cible thérapeutique ou diagnostique
WO2006010516A1 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine de type methionine aminopeptidase 2 (metap2-like)
WO2005075664A1 (fr) Methodes diagnostiques et therapeutiques des maladies associees au kallikrein 15 (klk15)
WO2005040402A2 (fr) Diagnostics et therapeutique de maladies associees a la dipeptidase 2 acide n-acetylee a liaison alpha (naaladase 2)
WO2005040401A2 (fr) Diagnostic et traitement de maladies associees a la serine-protease mosaique (msp)
WO2004071377A2 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies a la photodiesterase 3a (pde3a)
US20070202567A1 (en) Diagnostics And Therapeutics For Diseases Associated With Arginyl Aminopeptidase Rnpep (Rnpep)
EP1678319A1 (fr) Diagnostics et therapeutiques pour maladies associees a la dipeptidase acidique a liaison alpha n-acetylee de type 1 (naaladase de type 1)
WO2004101813A1 (fr) Methodes diagnostiques et therapeutiques pour maladies associees a l'antigene du systeme kell (kel)
US20070166715A1 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase-like 1 (npepl1)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20101011

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110104